Targeted Therapy for Lung Cancer (Faculty Presentations)

Total Page：16

File Type：pdf, Size：1020Kb

POST-TEST Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer (Faculty Presentations) THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. Which of the following disease-free 4. Interim results of the Phase II DESTINY- survival outcomes was reported at the Lung01 study, reported at the ASCO20 plenary session of the ASCO20 Virtual Virtual meeting, evaluating the antibody- meeting from the Phase III ADAURA drug conjugate trastuzumab deruxtecan trial evaluating osimertinib as adjuvant demonstrated promising clinical activity therapy for patients with Stage IB to IIIA with a high objective response rate non-small cell lung cancer (NSCLC) with and durable responses in patients with EGFR mutations after complete tumor nonsquamous NSCLC and which of the resection? following targetable mutations? a. Statistically significant and clini- a. ALK gene rearrangements cally meaningful improvement b. EGFR mutations versus placebo c. HER2 mutations b. Trend toward statistically significant d. MET exon 14 skipping mutations improvement versus placebo e. RET fusions c. No improvement versus placebo f. ROS1 rearrangements 2. Which of the following drug types best 5. Which of the following statements is true describes the mechanism of action of with regard to CNS activity in patients the recently FDA-approved agent selper- with NSCLC, ROS-1 rearrangement and catinib for patients with metastatic brain metastases undergoing treatment NSCLC? with a ROS-1 inhibitor? a. ALK inhibitor a. Crizotinib is more efficacious b. EGFR inhibitor than entrectinib c. HER2 inhibitor b. Entrectinib is more efficacious d. MET inhibitor than crizotinib e. RET inhibitor c. Neither a nor b (these agents f. ROS1 inhibitor exhibit equivalent CNS activity) 3. Capmatinib was recently FDA approved 6. Which of the following conditions for patients with metastatic NSCLC with has been reported as an adverse which of the following genomic altera- event of special interest in patients tions? with HER2-mutated NSCLC receiving a. EGFR mutations trastuzumab deruxtecan? b. RET fusions a. New secondary cancer c. MET exon 14 skipping mutations b. Ocular toxicities c. Interstitial lung disease 7. Which of the following agents is not a selective RET inhibitor? a. Selpercatinib b. Pralsetinib c. Cabozantinib QID 2691 POST-TEST Recent Advances in Medical Oncology: Targeted Therapy for Lung Cancer (Faculty Presentations) THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 8. Emerging data evaluating targeted 10. Which of the following agents would therapy for patients with NSCLC with be most effective for a patient with EGFR exon 20 insertions demonstrate metastatic NSCLC and a TRK gene promising activity with which of the fusion? following agents? a. Trastuzumab deruxtecan a. Mobocertinib (TAK-788) b. Capmatinib b. Erlotinib c. Larotrectinib c. Afatinib 9. The Phase III ALEX study investigating the efficacy of alectinib versus crizotinib in patients with untreated advanced NSCLC with ALK rearrangements demonstrated which of the following progression-free survival (PFS) outcomes? a. Longer PFS with crizotinib b. Longer PFS with alectinib c. Similar PFS in both study arms QID 2691.

Copy Link

Recommended publications

Cstone's Partner Blueprint Medicines Presented Updated Part 1 Data from PIONEER Trial of Avapritinib
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development. CStone Pharmaceuticals 基石藥業 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 2616) VOLUNTARY ANNOUNCEMENT CSTONE’S PARTNER BLUEPRINT MEDICINES PRESENTED UPDATED PART 1 DATA FROM PIONEER TRIAL OF AVAPRITINIB SHOWING ROBUST REDUCTIONS IN CUTANEOUS DISEASE SYMPTOMS IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS The partner of CStone Pharmaceuticals (the “Company” or “CStone”), Blueprint Medicines Corporation (NASDAQ: BPMC) (“Blueprint Medicines”), announced on June 6 updated clinical data from part 1 of the PIONEER trial showing robust and consistent clinical activity for avapritinib across multiple qualitative and quantitative measures of cutaneous disease in patients with indolent systemic mastocytosis (“ISM”).
[Show full text]
Australian Public Assessment Report for Larotrectinib
Australian Public Assessment Report for Larotrectinib Proprietary Product Name: Vitrakvi Sponsor: Bayer Australia Limited December 2020 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
[Show full text]
Entrectinib (Interim Monograph)
Entrectinib (interim monograph) DRUG NAME: Entrectinib SYNONYM(S): RXDX-1011, NMS-E6282 COMMON TRADE NAME(S): ROZLYTREK® CLASSIFICATION: molecular targeted therapy Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Entrectinib is an orally administered, small molecule, multi-target tyrosine kinase inhibitor which targets tropomyosin- related kinase (Trk) proteins TrkA, TrkB, and TrkC, proto-oncogene tyrosine-protein kinase ROS (ROS1) and anaplastic lymphoma kinase (ALK). TrkA, TrkB, and TrkC are receptor tyrosine kinases encoded by the neurotrophic tyrosine receptor kinase (NTRK) genes NTRK1, NTRK2, and NTRK3, respectively. Fusion proteins that include Trk, ROS1, or ALK kinase domains drive tumorigenic potential through hyperactivation of downstream signalling pathways leading to unconstrained cell proliferation. By potently inhibiting the Trk kinases, ROS1, and ALK, entrectinib inhibits downstream signalling pathways, cell proliferation and induces tumour cell apoptosis.3-5 PHARMACOKINETICS: Oral Absorption bioavailability = 55%; Tmax = 4-6 hours; Tmax delayed 2 h by high-fat, high-calorie food intake Distribution highly bound to human plasma proteins cross blood brain barrier? yes volume of distribution 551 L (entrectinib); 81.1 L (M5) plasma protein binding >99% (entrectinib and M5) Metabolism primarily metabolized by CYP 3A4 active metabolite(s) M5 inactive metabolite(s) M11 Excretion primarily via hepatic clearance urine 3.06% feces 82.9% (36% as unchanged entrectinib, 22% as M5) terminal half life 20 h (entrectinib); 40 h (M5) clearance 19.6 L/h (entrectinib); 52.4 L/h (M5) Elderly no clinically significant difference Children comparable pharmacokinetics of entrectinib and M5 in adults and children Ethnicity no clinically significant difference Adapted from standard reference3,4 unless specified otherwise.
[Show full text]
Alectinib Provides a New Option for ALK-Positive NSCLC Patients After Progression on Crizotinib See Commentary on Page 239
Community Translations Edited by Jame Abraham, MD, FACP Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib See Commentary on page 239 n December 2015, alectinib became the third ALK inhibitor approved by the United States Food and What’s new, what’s important IDrug Administration for the treatment of non-small- The US Food and Drug Administration approved alectinib to cell lung cancer (NSCLC) that displays rearrangements of treat patients with metastatic ALK-positive non-small-cell lung the anaplastic lymphoma kinase (ALK) gene. Alectinib is cancer whose disease had progressed or who could not toler- a second-generation small molecule inhibitor of the ALK ate treatment with crizotinib. In clinical trials, alectinib showed a protein that joins ceritinib in providing a useful treatment partial response of 38%-44% and an average progression-free option for patients who have progressed on crizotinib, as survival of 11.2 months. In all, 61% of patients experienced a a result of its ability to target crizotinib-resistant mutant complete or partial reduction in their brain metastatic lesions, forms of the ALK protein. Alectinib also displays enhanced with a progression-free survival of of 9.1 months. The recom- penetrance of the blood-brain barrier, which improves ef- mended dose is 600 mg orally twice daily. cacy against central nervous system (CNS) metastases. The most common side effects are fatigue, constipation, swell- Te FDA awarded alectinib accelerated approval on the ing (edema), and muscle pain (myalgia). Treatment with alec- basis of 2 phase 2, single-arm clinical trials in patients tinib may cause sunburn when patients are exposed to sunlight, with ALK-positive NSCLC who had progressed on and pregnant women should be notifed of the possible risk to crizotinib therapy, a group of patients who have few avail- the fetus, and to use contraception throughout treatment and for able treatment options.
[Show full text]
Pharmaceutics of Oral Anticancer Agents and Stimulants
Pharmaceutics of oral anticancer agents and stimulants Maikel Herbrink The research in this thesis was performed at the Departments of Pharmacy & Pharma- cology and Medical Oncology & Clinical Pharmacology of the Netherlands Cancer Insti- tute – Antoni van Leeuwenhoek hospital, Amsterdam, the Netherlands. Printing of this thesis was financially supported by: Netherlands Cancer Institute Chipsoft BV Pfizer BV ISBN: 978-90-393-6997-5 Design, lay-out and print Gildeprint, Enschede © Maikel Herbrink, 2018 Pharmaceutics of oral anticancer agents and stimulants Farmaceutisch onderzoek naar oraal toegediende antikankermiddelen en stimulantia (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof. dr. H.R.B.M. Kummeling, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op woensdag 27 juni 2018 des middags te 4.15 uur door Maikel Herbrink geboren op 2 februari 1990 te Groningen Promotoren: Prof. dr. J.H. Beijnen Prof. dr. J.H.M. Schellens Copromotor: Dr. B. Nuijen Contents Preface 9 Chapter 1: Introduction 15 1.1 Variability in bioavailability of small molecular tyrosine 17 kinase inhibitors Cancer Treat Rev. 2015 May;41(5):412-422 1.2 Inherent formulation issues of kinase inhibitors 51 J Control Release. 2016 Oct;239:118-127 1.3 High-tech drugs in creaky formulations 81 Pharm Res. 2017 Sep;34(9):1751-1753 Chapter 2: Pharmaceutical analysis of oral anticancer drug substances 89 2.1. Thermal study of pazopanib hydrochloride 91 J Therm Anal Calorim. 2017 Dec;130(3):1491-1499 2.2.
[Show full text]
07052020 MR ASCO20 Curtain Raiser
Media Release New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non- small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020, 08:00 CEST Basel, 7 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 21 cancer types, will be presented at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO), which will be held 29-31 May, 2020. A total of 120 abstracts that include a Roche medicine will be presented at this year's meeting. "At ASCO, we will present new data from many investigational and approved medicines across our broad oncology portfolio," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “These efforts exemplify our long-standing commitment to improving outcomes for people with cancer, even during these unprecedented times. By integrating our medicines and diagnostics together with advanced insights and novel platforms, Roche is uniquely positioned to deliver the healthcare solutions of the future." Together with its partners, Roche is pioneering a comprehensive approach to cancer care, combining new diagnostics and treatments with innovative, integrated data and access solutions for approved medicines that will both personalise and transform the outcomes of people affected by this deadly disease.
[Show full text]
Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK
cancers Systematic Review Comparative Efﬁcacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis Koichi Ando 1,2,* , Ryo Manabe 1, Yasunari Kishino 1, Sojiro Kusumoto 1, Toshimitsu Yamaoka 3 , Akihiko Tanaka 1, Tohru Ohmori 1,4 and Hironori Sagara 1 1 Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan; [email protected] (R.M.); [email protected] (Y.K.); [email protected] (S.K.); [email protected] (A.T.); [email protected] (T.O.); [email protected] (H.S.) 2 Division of Internal Medicine, Showa University Dental Hospital Medical Clinic, Senzoku Campus, Showa University, 2-1-1 Kita-senzoku, Ohta-ku, Tokyo 145-8515, Japan 3 Advanced Cancer Translational Research Institute, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan; [email protected] 4 Department of Medicine, Division of Respiratory Medicine, Tokyo Metropolitan Health and Hospitals Corporation, Ebara Hospital, 4-5-10 Higashiyukigaya, Ohta-ku, Tokyo 145-0065, Japan * Correspondence: [email protected]; Tel.: +81-3-3784-8532 Citation: Ando, K.; Manabe, R.; Kishino, Y.; Kusumoto, S.; Yamaoka, Simple Summary: The treatment of anaplastic lymphoma kinase (ALK) rearrangement-positive T.; Tanaka, A.; Ohmori, T.; Sagara, H. (ALK-p) advanced non-small cell lung cancer (NSCLC) remains a challenge.
[Show full text]
Cogent Biosciences Announces Creation of Cogent Research Team
Cogent Biosciences Announces Creation of Cogent Research Team April 6, 2021 Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million supports company goals into 2024, including three CGT9486 clinical trials on-track to start this year, beginning with ASM in 1H21 BOULDER, Colo. and CAMBRIDGE, Mass., April 6, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the formation of the Cogent Research Team led by newly appointed Chief Scientific Officer, John Robinson, PhD. "Today marks an important step forward for Cogent Biosciences as we announce the formation of the Cogent Research Team with a focus on discovering and developing new small molecule therapies for patients fighting rare, genetically driven diseases," said Andrew Robbins, President and Chief Executive Officer of Cogent Biosciences. "I am thrilled to welcome John onboard as Cogent Biosciences' Chief Scientific Officer. John's expertise and seasoned leadership make him ideally suited to lead this new team of world class scientists. Given the team's impressive experience and accomplishments, we are excited for Cogent Biosciences' future and the opportunity to expand our pipeline and deliver novel precision therapies for patients." With an exceptional track record of innovation, the Cogent Research Team will focus on pioneering best-in-class, small molecule therapeutics to both improve upon existing drugs with clear limitations, as well as create new breakthroughs for diseases where others have been unable to find solutions.
[Show full text]
Phase II Study of Selumetinib, an Orally Active Inhibitor of MEK1 and MEK2 Kinases, in KRASG12R-Mutant Pancreatic Ductal Adenocarcinoma
UC Davis UC Davis Previously Published Works Title Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. Permalink https://escholarship.org/uc/item/3520819s Journal Investigational new drugs, 39(3) ISSN 0167-6997 Authors Kenney, Cara Kunst, Tricia Webb, Santhana et al. Publication Date 2021-06-01 DOI 10.1007/s10637-020-01044-8 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Investigational New Drugs (2021) 39:821–828 https://doi.org/10.1007/s10637-020-01044-8 SHORT REPORT Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma Cara Kenney1 & Tricia Kunst1 & Santhana Webb1 & Devisser Christina Jr2 & Christy Arrowood3 & Seth M. Steinberg4 & Niharika B. Mettu3 & Edward J. Kim2 & Udo Rudloff1,5 Received: 5 November 2020 /Accepted: 3 December 2020 / Published online: 6 January 2021 # This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020 Summary Background Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We con- ducted a biomarker-driven trial of selumetinib (KOSELUGO™; ARRY-142886), an orally active, allosteric mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, in pancreas cancer patients with somatic KRASG12R mutations. Methods In this two- stage, phase II study (NCT03040986) patients with advanced pancreas cancer harboring somatic KRASG12R variants who had received at least one standard-of-care systemic therapy regimen received 75 mg selumetinib orally twice a day until disease progression or unacceptable toxicity occurred.
[Show full text]
Tabrecta (Capmatinib)
Tabrecta (capmatinib) NEW PRODUCT SLIDESHOW Introduction . Brand name: Tabrecta . Generic name: Capmatinib . Pharmacologic class: Kinase inhibitor . Strength and Formulation: 150mg, 200mg; tablets . Manufacturer: Novartis . How supplied: Tabs—56 . Legal Classification: Rx Tabrecta Indication Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA- approved test . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) Dosage and Administration Confirm presence of a mutation that leads to MET exon 14 skipping in tumor specimens Swallow whole 400mg twice daily Recommended dose reductions for adverse reactions: . First: 300mg twice daily . Second: 200mg twice daily . Permanently discontinue in patients unable to tolerate 200mg twice daily Dosage Modifications for Adverse Reactions Interstitial lung disease/pneumonitis . Any grade: permanently discontinue Increased ALT and/or AST without increased total bilirubin . Grade 3: withhold until recovery to baseline ALT/AST; if recovery to baseline within 7 days, then resume at same dose, otherwise resume at a reduced dose . Grade 4: permanently discontinue Increased ALT and/or AST with increased total bilirubin in the absence of cholestasis or hemolysis . ALT and/or AST >3xULN with total bilirubin >2xULN: permanently discontinue Dosage Modifications for Adverse Reactions Increased total bilirubin without concurrent increased ALT and/or AST . Grade 2: withhold until recovery to baseline bilirubin; if recovered to baseline within 7 days, then resume at same dose, otherwise resume at reduced dose . Grade 3: withhold until recovery to baseline bilirubin; if recovered to baseline within 7 days, then resume at reduced dose, otherwise permanently discontinue .
[Show full text]
Incyte Corporation
Building Value through Innovative Medicines 2019 First Quarter Financial and Corporate Update April 30, 2019 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: expectations regarding ruxolitinib, ruxolitinib cream, itacitinib, pemigatinib, parsaclisib and INCMGA0012 trial results and timing of the receipt and presentation of those results; the expected timing of the NDA submissions for pemigatinib and capmatinib; our belief that certain of our projects, such as the acceleration of vitiligo development and opportunities with pemigatinib and itacitinib, warrant increased near-term funding; expectations regarding planned regulatory updates, planned pivotal clinical updates and planned clinical trial initiations; expectations by our collaborative partners regarding timing of NDA submission for capmatinib and announcement of baricitinib trial results; our plans and expectations for development of, and clinical trials involving, our other product candidates, including the potential timing for regulatory submissions; our plans for immediate launch of ruxolitinib for steroid-refractory acute GVHD should the FDA approve our sNDA; our updated 2019 GAAP and non-GAAP guidance; our expectations regarding baricitinib royalties; and our expected 2019 newsflow events. These forward-looking statements are based on our current expectations and are subject to risks
[Show full text]
Patient Group Input Submissions
CBCN’s 2012 Metastatic Breast Cancer Patient and Caregiver Survey Report: An online survey was distributed to patients living with metastatic breast cancer and their caregivers. No patients surveyed had experience with the treatment under review. Survey questions comprised of a combination of scoring options and free form commentary. Patients were contacted through the membership databases of CBCN and other patient organizations. -71 patients participated in the survey -16 caregivers participated in the survey Printed sources: A review was conducted of current studies and grey literature to identify issues and experiences that are commonly shared among many women living with metastatic breast cancer. 3. Disease Experience Metastatic breast cancer is the spread of cancerous cell growth to areas of the body other than where the cancer first formed. It is most commonly spread to the bones, but can include the lungs, liver, brain and skin. Triple-negative breast cancer (TNBC) is breast cancer that is estrogen-receptor-negative, progesterone-receptor-negative and HER2-negative. Accounting for 12-17% of breast cancers, TNBC’s have been shown to be relatively aggressive and display a high risk of metastasis and death within 5 years after diagnosis. TNBC is considered to be vastly heterogeneous and is often used as an umbrella term, encompassing a wide spectrum of entities with marked genetic, transcriptional, histological, and clinical differences. 1 A rare cancer that is more commonly associated with TNBC, is secretory breast carcinomas- a cancer that occurs due to an over secretion of mucin in the tumor. It is considered a subtype of invasive ductal carcinoma but is prone to metastasis and local recurrence.
[Show full text]